Review role of topotecan in gynaecological cancers: Current indications and perspectives

Lorusso, Domenica; Pietragalla, Antonella; Mainenti, S.; Masciullo, Valeria; Vagno, Giovanni Di; Scambia, Giovanni

doi:10.1016/j.critrevonc.2009.08.001

Cited by 54 publications

(40 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7). Topotecan (Hycamtin) is a topoisomerase I inhibitor that acts by stabilizing the single-stranded DNA (ssDNA)-topoisomerase I complex and causing DNA cleavage (62). It is currently used in chemotherapy for various cancers.…”

Section: Discussionmentioning

confidence: 99%

Phenothiazines Inhibit Hepatitis C Virus Entry, Likely by Increasing the Fluidity of Cholesterol-Rich Membranes

Chamoun‐Emanuelli

Pécheur

Simeon

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Despite recent progress in the development of direct-acting antiviral agents against hepatitis C virus (HCV), more effective therapies are still urgently needed. We and others previously identified three phenothiazine compounds as potent HCV entry inhibitors. In this study, we show that phenothiazines inhibit HCV entry at the step of virus-host cell fusion, by intercalating into cholesterol-rich domains of the target membrane and increasing membrane fluidity. Perturbation of the alignment/packing of cholesterol in lipid membranes likely increases the energy barrier needed for virus-host fusion. A screening assay based on the ability of molecules to selectively increase the fluidity of cholesterol-rich membranes was subsequently developed. One compound that emerged from the library screen, topotecan, is able to very potently inhibit the fusion of liposomes with cell culture-derived HCV (HCVcc). These results yield new insights into HCV infection and provide a platform for the identification of new HCV inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

Phenothiazines Inhibit Hepatitis C Virus Entry, Likely by Increasing the Fluidity of Cholesterol-Rich Membranes

Chamoun‐Emanuelli

Pécheur

Simeon

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Worldwide, chemotherapy has been used in recurrent cervical carcinoma with variable results. [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] At present, cisplatin in combination with paclitaxel is the standard-of-care chemotherapy in the palliative management of cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Palliative chemotherapy in recurrent carcinoma cervix: experience from a regional cancer centre in southern India

Bonanthaya

Lakshmaiah

Babu

et al. 2016

Southern African Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Aims:To evaluate the clinical outcome and complications with two different palliative chemotherapy regimens in recurrent cervical carcinoma. Methods and materials: Forty (40) women with recurrent cervical squamous cell carcinoma were treated with palliative chemotherapy using paclitaxel plus cisplatin or single-agent docetaxel. Clinical outcome and toxicities were analysed. The parameters in two arms were compared using Student's t-test and statistical analysis was done using R software. Results: At a median follow up of 1.35 years the clinical outcome was complete response/partial response in 50% and 60% and progressive disease in 20% and 10% of the patients with either paclitaxel/cisplatin or docetaxel, respectively, which was not statistically significant. Stable disease (SD) was 30% in both arms. Toxicity included nausea, seen in all the patients in both arms, and diarrhoea, seen in 90% and 70% of the patients in the two arms, respectively. Grade II to III neutropenia was seen in 10% of patients with paclitaxel/cisplatin and none with docetaxel. Hypersensitivity was encountered in 40% and 30% in the two arms, respectively. Conclusion: There was no significant difference in clinical outcome and morbidity in patients with either paclitaxel/cisplatin or single-agent docetaxel. Further prospective clinical trials with larger study groups and longer follow-up are required to substantiate these claims.

show abstract

“…A mielotoxicidade é a principal complicação. Não são observados efeitos tóxicos no sistema cardiovascular 202 .…”

Section: -Inibidores De Topoisomerase E Epidoflotoxinasunclassified

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Filho¹,

Hajjar²,

Bacal³

et al. 2011

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

Review role of topotecan in gynaecological cancers: Current indications and perspectives

Cited by 54 publications

References 79 publications

Phenothiazines Inhibit Hepatitis C Virus Entry, Likely by Increasing the Fluidity of Cholesterol-Rich Membranes

Phenothiazines Inhibit Hepatitis C Virus Entry, Likely by Increasing the Fluidity of Cholesterol-Rich Membranes

Palliative chemotherapy in recurrent carcinoma cervix: experience from a regional cancer centre in southern India

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Contact Info

Product

Resources

About